Drug intelligence / Profile preview

CCHF DNA

Development stage: Unknown
Lead developer: SVF Vaccines
Modality: DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

CCHF DNA is a DNA-based prophylactic vaccine candidate developed by SVF Vaccines for the prevention of Crimean-Congo Hemorrhagic Fever (CCHF). As a DNA vaccine, it is designed to deliver genetic sequences encoding viral antigens into host cells to stimulate an immune response against the CCHF virus. The project is identified by the developer as a precursor program with no current intellectual property (IP) associated and is listed as being in Phase 1 development.

Beyond the preview

Go deeper on CCHF DNA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CCHF DNA.

Explore the full profile